Clinical Trial Update: Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating an oxygen-enhanced MRI method in COPD patients over 8 weeks while treated with Symbicort Turbuhaler or Oxis Turbuhaler.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Oxis Turbuhaler (formoterol)
• Symbicort Turbuhaler (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation | EARLY_Phase 1 | Status: COMPLETED